|
Mutation Information
|
Mutation Site
|
M250V |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Combined Mutation
|
rt.L180M+rt.M204I+rt.M250V;rt.L180M+rt.M204I+rt.M204V+rt.M250V;rt.L180M+rt.M204I+rt.M204V+rt.M250L+rt.M250V;rt.L180M+rt.M204V+rt.M250V+rt.T184L;rt.L180M+rt.M204V+rt.M250V;rt.L180M+rt.M204V+rt.M250V+rt.T184A;rt.M250V+rt.M204V+rt.A181C+rt.L180M |
|
Genotype/Subtype
|
B;C |
|
Relevant Drug
|
entecavir (ETV);interferon(IFN);lamivudine (LAM);adefovir dipivoxil (ADV);tenofovir (TDF) |
|
Country
|
China |
Literature Information
|
PubMed PMID
|
30866789
|
|
Disease
|
HBV infection
|
|
Published Year
|
2019 |
|
Journal
|
Emerging microbes & infections |
|
Title
|
Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice. |
|
Author
|
Liu Y,Zhou Y,Li X,Niu M,Chen R,Shao J,Si L,Luo D,Lin Y,Li L,Zhang K,Xiao X,Xu Z,Liu M,Lu M,Zoulim F,Xu D |
|
Evidence
|
Patient-derived representative rtA181C-containing mutants, rtL180M+A181C+M204V, rtL180M+A181C+M204V+M250V, and rtL180M+A181C+S202G+M204V, exhibited 45.7%, 25.9%, and 25.0% replication capacity and 85.6-, 356.1-, and 307.1-fold decreased susceptibility to ETV respectively compared to the wild-type strain, while the three mutants remained sensitive to tenofovir (TDF).
|
|
|
HBV Mutation Detail Information